What the screen asks for
The low-drawdown equity screen sits in the screener's Risk-adjusted returns group. Its rule:
- the fund is an equity fund,
- its maximum drawdown is shallower than 20%, and
- its three-year CAGR is above 12%.
The page adds its own housekeeping: Direct plans only, Growth option, no segregated portfolios or schemes that have stopped publishing a NAV. It ranks the funds that pass by three-year CAGR. There is no size floor.
The pairing makes sense. A return figure says what you ended with; a drawdown says what the worst stretch felt like on the way, which is often the moment people sell. A fund that delivered 12% or more without a 20% fall would have been easier to hold.
One detail decides almost everything about the result: the drawdown is measured over the fund's whole history, from its first NAV to 9 October 2026, not over a fixed window.
How many pass
Of 418 Direct equity funds with a three-year record, 210 beat 12% a year. Only 31 of those also never fell 20%. The ten with the highest three-year CAGR, as of NAVs to 9 October 2026:
| Fund | Type | 3Y CAGR | Worst fall | First NAV | AUM (₹ Cr) |
|---|---|---|---|---|---|
| HDFC Pharma and Healthcare | Healthcare | 29.29% | -14.91% | Oct 2023 | 3,128 |
| Mirae Asset Healthcare | Healthcare | 21.95% | -19.98% | Jul 2018 | 3,458 |
| LIC MF Healthcare | Healthcare | 20.87% | -15.10% | Jul 2023 | 99 |
| WhiteOak Capital Mid Cap | Mid cap | 20.63% | -19.33% | Sep 2022 | 7,096 |
| ITI Pharma and Healthcare | Healthcare | 18.73% | -17.69% | Nov 2021 | 266 |
| Axis Multicap | Multi cap | 18.47% | -18.08% | Dec 2021 | 11,430 |
| ICICI Prudential Innovation | Thematic | 18.07% | -16.51% | May 2023 | 7,836 |
| Tata India Pharma & Healthcare | Healthcare | 17.89% | -19.84% | Dec 2015 | 1,534 |
| WhiteOak Capital Multi Cap | Multi cap | 17.65% | -16.93% | Sep 2023 | 4,222 |
| LIC MF Multi Cap | Multi cap | 17.11% | -19.32% | Nov 2022 | 2,173 |
AUM is each scheme's average for July to September 2026, all plans together.
What fills the list
Healthcare funds. Five of the 31, including both funds older than 2020. Neither fell 20% in March 2020, when the Nifty 50 index fund fell 38.42%: Mirae Asset Healthcare's worst fall came then, at 19.98%, just inside the line.
Multi cap and flexi cap funds: seven multi cap and five flexi cap. The other 14 are three ELSS, two value, two mid cap, one focused, one large cap and five more thematic funds (three business cycle, one innovation, one financial services).
One fund house more than any other. WhiteOak Capital has five of the 31: its mid cap, multi cap, flexi cap, ELSS and large cap funds, all launched in 2022 or 2023.
Small funds. With no AUM floor, LIC MF Healthcare at ₹99 crore sits beside ICICI Prudential Flexi Cap, the largest in the list at ₹24,586 crore (14.96% over three years, worst fall 19.71%).
Why the list is so young
29 of the 31 funds published their first NAV after the March 2020 crash. The oldest of those, DSP Value Fund, began in December 2020; 25 of the 31 have no five-year record at all.
That is the full-history drawdown at work. The UTI Nifty 50 Index Fund fell 38.42% at its worst, in March 2020; its worst fall in the last three years was 15.51%. Among the 279 Direct equity funds with NAVs from before 2020, the median worst-ever fall is 36.94%, and only 3 of the 279 have never fallen 20%. An older fund cannot pass this screen unless it dodged 2020, as the pharma funds did.
The younger funds' worst moments came later and were shallower. For 26 of the 31, the deepest fall bottomed between February and April 2025.
If every fund were judged on its worst fall in the last three years instead, 97 would pass rather than 31. Our post on the worst fall in three years by category uses that common window.
What it leaves out
- Nearly every fund that lived through 2020, however well it has done since.
- Small-cap funds. None pass; their falls have been deeper.
- Funds under three years old, which have no three-year CAGR to test.
- Hybrid funds, which are not in the equity category even when they hold mostly shares.
How to read it
A shallow drawdown in a short life is not proof of a shallow fund. A fund launched in 2023 has not met a fall like 2020's. Its -17% may be a good portfolio or a calm three years. The screen cannot tell which, and neither can we.
Compare like with like. Before reading much into the worst-fall column, check each fund's first NAV date on its page. Axis Multicap vs WhiteOak Capital Multi Cap puts two of the multi caps side by side; their records start almost two years apart.
Drawdown is one measure among several. Volatility, Sortino and capture ratios describe the ride differently; risk-adjusted returns explains how they fit together.
The list moves. The screen reruns on every day's NAVs. One sharp fall can push a fund past -20% for good, since a full-history drawdown never shrinks, and a fund turning three can join.
These are past figures computed from each fund's NAV history. A screen narrows a list; it does not rank funds by merit, and nothing here is a recommendation to buy or sell any of them.
Frequently asked questions
Which equity funds never fell more than 20% and still returned over 12% a year?
As of NAVs to 9 October 2026, 31 Direct equity funds had a worst-ever fall shallower than 20% and a three-year CAGR above 12%. HDFC Pharma and Healthcare led at 29.29% a year with a worst fall of 14.91%, followed by Mirae Asset Healthcare at 21.95%.
Why are most funds in the low-drawdown equity screen less than five years old?
The screen reads each fund's maximum drawdown over its whole history. Funds with NAVs before 2020 lived through the March 2020 crash, and the median one among 279 such funds fell 36.94% at its worst. 29 of the 31 funds that pass began after that crash.
How far did the Nifty 50 fall in March 2020 compared with recent years?
The UTI Nifty 50 Index Fund's worst fall since 2013 was 38.42%, in March 2020. Its worst fall in the last three years was 15.51%.
This is commentary on published data, not investment advice. WealthTicker is not a SEBI-registered adviser or distributor. Figures are WealthTicker’s own calculations from public data — AMFI’s fund NAVs and disclosures, NSE’s index and FII/DII files, and the fund houses’ monthly portfolios (how we calculate). They are as of the dates stated and can be revised by their source.
Keep reading
Consistent compounders screen: 58 funds, gold at the top
58 funds beat 15% a year over both 3 and 5 years with ₹1,000 crore or more in assets. Gold and US funds fill the top ten; no large-cap fund qualifies.
Decade compounders: 69 funds beat 15% a year for 10 years
69 funds of ₹1,000 crore or more compounded above 15% a year over the ten years to October 2026. No large-cap or index fund made it; Quant has 9 of the 69.
Falls less than it rises: 74 funds, 29 pharma or hybrid
74 funds caught over 95% of their benchmark's rising months and under 85% of its falls. 14 of 15 pharma funds pass; 3 of 97 large, mid and flexi caps do.
